The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN Practice Guidelines in Oncology: Prostate cancer (The Complete Library of Practice Guidelines in Oncology [CD-ROM]).Rockledge, PA: National Comprehensive Cancer Network; 2001.
2.
CulineS., DrozJ.P.Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: A decade of progress?Ann Oncol.2000; 11: 1523–30.
3.
HarrisK.A., ReeseD.M.Treatment options in hormonerefractory prostate cancer—current and future approaches.Drugs.2001; 61: 2177–92.
4.
HudesG.R., GreenbergR., KrigalR.L.Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.J Clin Oncol.1992; 10: 1754–61.
5.
HudesG., EinhornL., RossE.Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.J Clin Oncol.1999; 17: 3160–6.
6.
SeidmanA.D., ScherH.I., PetrylakD.Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.J Urol.1992; 147: 931–4.
7.
AttivissimoL.A., FettenJ.V., KreisW.Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.Am J Clin Oncol (CCT).1996; 19: 581–3.
8.
AlbrechtW., HorenblasS., MarechalJ.M.Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with hormone escaped progressive metastatic prostate cancer [abstract].Proc Am Soc Clin Oncol.1998; 17: 101a.
9.
AmatoR.J., EllerhorstJ., BuiC.Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate.Urol Oncol.1995; 1: 168–72.
10.
SellaA., FlexD., KonichezkyM.Combination chemotherapy following adrenal suppression in androgen-independent prostate cancer.Eur Urol.2000; 38: 255–8.
11.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
12.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
13.
National Comprehensive Cancer Network.NCCN Antiemesis Practice Guidelines. (The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]).Rockledge, PA: National Comprehensive Cancer Network; 2001.
14.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
15.
MorrowG.R., HickockJ.T., RosenthalS.N.Progress in reducing nausea and emesis: Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropesetron (Navoban).Cancer.1995; 76: 343–57.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
20.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6: 145–51.
21.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36: S15–S21.
22.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–9, 63–7,70–4.
23.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49: 1796–9.
24.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–405.
25.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
26.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–90.
